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The clinical entity collectively known as glaucoma is a 
very specific optic neuropathy that affects individuals 
with various degrees of ocular complications and 
even with greater degrees of genetic heterogeneity.[1,2] 
Although the very first genetic contribution to this group 
of eye disorders was described over 50 years ago,[3] it took 
another 30 years before the first molecular studies of this 
condition were undertaken.[4,5] The significant challenge 
in understanding the basic underlying genes, proteins, 
biochemical and molecular pathways that are involved 
in this group of disorders is due to many difficulties in 
accurate clinical diagnosis, classification, primary vs. 
secondary disease, as well as various degrees of both 
clinical and genetic heterogeneity.[6,7] Furthermore, lack 
of suitable large families, extreme ages of onset, racial 
ethnicity and many other limiting factors compound 
our ability to find the majority of defective genes and 
proteins for this ocular condition.
It is against this background that finding or even 
relating certain mutations in one or more genes and their 
possible contributions to a specific form of glaucoma 
would be a significant addition to our understanding 
of the molecular basis of this condition. One such study 
is the current paper by Safari et al[8] in which they studied 
the possible role of the LTBP2 gene in the etiology of 
primary angle closure glaucoma (PACG) as well as 
a single case with both PACG and pseudoexfoliation 
glaucoma (PXFG). Although the LTBP2 gene was 
originally reported to be the cause of primary congenital 
glaucoma (PCG) in certain Pakistani[9] and Iranian[10] 
families, subsequent studies by other investigators 
failed to confirm this observation in a group of 
American[11,12] Turkish,[12] English,[12] Indian[13] and 
Saudi Arabian[14] PCG subjects. It is likely that the 
congenital glaucoma nature of patients reported in the 
earlier studies[9,10] were in fact of a secondary nature, 
as those patients had a series of other ocular and 
non‑ocular complications. Moreover, many other LTBP2 
mutations have now been reported in megalocornea,[15] 
spherophakia,[15] microspherophakia,[15,16] ectopia lentis[17] 
and Weill‑Marchesani syndrome.[18] Interestingly, often 
these disorders are reported with secondary forms of 
glaucoma. Also, it has recently been reported that other 
Common Molecular Challenges in Glaucoma
Mansoor Sarfarazi, PhD
Molecular Ophthalmic Genetics Laboratory, Department of Surgery, University of Connecticut Health Center, Farmington, CT, USA
LTBP2 sequence variations may contribute to the etiology 
of primary open angle glaucoma (POAG) and PXFG.[19]
In the current paper by Safari et al[8] the authors 
investigated the possibility of LTBP2 involvement in 
a group of PACG subjects. They sequenced a total of 
54 PACG subjects for this gene and identified a number 
of interesting sequence variations. After careful scrutiny 
of the observed DNA variations, they concluded that 
2 of the original 24 sequence changes may contribute to 
the disease status of one subject with PACG and another 
with both PACG and PXFG (Q1417R and G1660W, 
respectively). This is the first systematic investigation 
of LTBP2 gene mutations in a group of PACG subjects.
Although this is a very interesting report, one has to 
note that the same two mutations of Q1417R and G1660W 
are also identified in the South Asian subjects, though 
no specific clinical manifestation has been reported for 
these individuals. For Q1417R (rs137854863), the ExAC 
Browser[20] reports 6 out of 16,506 South Asians and one 
out of 66,148 Europeans to have the same mutation. For 
G1660W (rs147223742), the comparable frequencies are 
64 out of 16,512 South Asians and 1 out of 902 subjects 
from other unspecified populations. It is very interesting 
that these two mutations are reported primarily in 
South Asian populations with a known high frequency 
of PACG, as compared to other regions. Therefore, it is 
likely that the two mutations reported by Sarafi et al[8] 
are possibly involved in the PACG phenotype. However, 
ultimate proof for such observation can only be 
demonstrated by proper functional studies of these two 
mutations.
It is equally likely that LTBP2 mutations will 
be reported for many other ocular and non‑ocular 
conditions. Experience from exome sequencing data on 
over 60,000 individuals[20] now clearly shows that many 
such individual mutations are present in other clinical 
entities and in other ethnically related individuals. 
Furthermore, as during exome or whole‑genome 
sequencing over 25,000 genes are being simultaneously 
sequenced, for any given subject, hundreds of individual 
unique and previously unreported DNA variations 
are often observed. Therefore, the task of relating 
each of these uniquely observed DNA variations to a 
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specific clinical phenotype of an individual remains 
a significant challenge. Different uniquely‑identified 
gene mutations are logically expected to have an ending 
clinical expression on a given phenotype. However, 
many of such clinical entities may have not even been 
discovered as yet or at least not identified in the person 
that has been sequenced. Therefore, presence of a single 
mutation in one or more affected subject is no longer 
indicative of its being specific and disease causing; the 
biological significance of such specific mutations and 
their individual causative nature may have to be shown 
first. This is even more relevant when a specific mutation 
is being reported for the first time in a new clinical entity. 
However, if a significant number of individuals show one 
or more mutations in the same gene and for the same 
new phenotype, then the likelihood for involvement 
of that gene in the etiology of that condition becomes 
increasingly higher.
Over the last 25 years a variety of glaucoma families 
and sporadic cases have been investigated by various 
molecular genetics techniques but only a handful of 
causative genes and a number of other specific gene 
associations have been identified.[21] The first two 
identified glaucoma genes, i.e. MYOC[22] and CYP1B1,[23] 
have been extensively studied in juvenile‑onset and 
congenital cases around the world and well‑proven to 
be involved in a significant proportion of subjects.[21] 
Moreover, these two genes have also been reported not 
only in glaucoma, but also in a number of other ocular 
disorders.[24‑27] This is indicative of the fact that mutations 
in one specific gene may be responsible for various 
subtypes of a common clinical entity or completely 
different unrelated disorders. The study by Safari et al[8] 
was an investigative approach to the same common goal.
Although a number of gene mutations have been 
identified for other glaucoma subtypes (POAG, NTG, 
PACG, PXFG)[21] and similarly, a group of other common 
polymorphic DNA markers have been shown to be 
associated with a specific glaucoma subtype,[21] none of 
these as yet has been identified as a single gene or an 
association that would be responsible for the majority 
of a primary form of a given glaucoma subtype. This 
in turn confirms the fact that a very large number of 
genes (perhaps several hundred) may be involved in 
the etiology of various forms of glaucoma and more 
specifically for different forms of POAG and other types 
of secondary glaucoma.
Given our limited success in understanding the 
molecular and biochemical pathways that lead to 
primary forms of various glaucoma subtypes, any 
specific contribution that may shed light on such 
challenging studies will be a welcome addition toward 
this common goal. Given the anticipated large number of 
genes that are expected to be involved in various forms 
of glaucoma, it may be many more years of extensive 
molecular investigation before we can have a better 
understanding of this devastating clinical phenotype 
that lead to blindness in many people around the world.
REFERENCES
1. Quigley HA, Broman AT. The number of people with glaucoma 
worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262‑267.
2. Shields MB. The challenge of screening for glaucoma. Am J 
Ophthalmol 1995;120:793‑795.
3. Crombie AL, Cullen JF. Hereditary glaucoma occurrence 
in five generations of an edinburgh family. Br J Ophthalmol 
1964;48:143‑147.
4. Sheffield VC, Stone EM, Alward WL, Drack AV, Johnson AT, 
Streb LM, et al. Genetic linkage of familial open angle glaucoma 
to chromosome 1q21‑q31. Nat Genet 1993;4:47‑50.
5. Stoilova D, Child A, Trifan OC, Crick RP, Coakes RL, Sarfarazi M. 
Localization of a locus (GLC1B) for adult‑onset primary open 
angle glaucoma to the 2cen‑q13 region. Genomics 1996;36:142‑150.
6. Allingham RR, Damji KF, Freedman S, Moroi SE, Shafranov G, 
Shields MB. Clinical Epidemiology of Glaucoma. 5th ed. 
Philadelphia: Lippincott Williams and Wilkins; 2005. p. 170‑190.
7. Sarfarazi M. Recent advances in molecular genetics of glaucomas. 
Hum Mol Genet 1997;6:1667‑1677.
8. Safari I, Akbarian S, Yazdani S, Elahi E. A possible role for LTBP2 
in the etiology of primary angle closure glaucoma. J Ophthalmic 
Vis Res 2015;10:123‑129.
9. Ali M, McKibbin M, Booth A, Parry DA, Jain P, Riazuddin SA, et al. 
Null mutations in LTBP2 cause primary congenital glaucoma. Am 
J Hum Genet 2009;84:664‑671.
10. Narooie‑Nejad M, Paylakhi SH, Shojaee S, Fazlali Z, Rezaei 
Kanavi M, Nilforushan N, et al. Loss of function mutations in the 
gene encoding latent transforming growth factor beta binding 
protein 2, LTBP2, cause primary congenital glaucoma. Hum Mol 
Genet 2009;18:3969‑3977.
11. Lim SH, Tran‑Viet KN, Yanovitch TL, Freedman SF, Klemm T, 
Call W, et al. CYP1B1, MYOC, and LTBP2 mutations in primary 
congenital glaucoma patients in the United States. Am J 
Ophthalmol 2013;155:508‑517.e5.
12. Sharafieh R, Child AH, Khaw PT, Fleck B, Sarfarazi M. LTBP2 gene 
analysis in the GLC3C‑linked family and 94 CYP1B1‑negative 
cases with primary congenital glaucoma. Ophthalmic Genet 
2013;34:14‑20.
13. Mohanty K, Tanwar M, Dada R, Dada T. Screening of the LTBP2 
gene in a north Indian population with primary congenital 
glaucoma. Mol Vis 2013;19:78‑84.
14. Abu‑Amero KK, Osman EA, Mousa A, Wheeler J, Whigham B, 
Allingham RR, et al. Screening of CYP1B1 and LTBP2 
genes in Saudi families with primary congenital glaucoma: 
Genotype‑phenotype correlation. Mol Vis 2011;17:2911‑2919.
15. Désir J, Sznajer Y, Depasse F, Roulez F, Schrooyen M, Meire F, et al. 
LTBP2 null mutations in an autosomal recessive ocular syndrome 
with megalocornea, spherophakia, and secondary glaucoma. Eur 
J Hum Genet 2010;18:761‑767.
16. Kumar A, Duvvari MR, Prabhakaran VC, Shetty JS, Murthy GJ, 
Blanton SH. A homozygous mutation in LTBP2 causes isolated 
microspherophakia. Hum Genet 2010;128:365‑371.
17. Khan AO, Aldahmesh MA, Alkuraya FS. Congenital megalocornea 
with zonular weakness and childhood lens‑related secondary 
glaucoma‑a distinct phenotype caused by recessive LTBP2 
mutations. Mol Vis 2011;17:2570‑2579.
18. Haji‑Seyed‑Javadi R, Jelodari‑Mamaghani S, Paylakhi SH, 
Yazdani S, Nilforushan N, Fan JB, et al. LTBP2 mutations 
cause Weill‑Marchesani and Weill‑Marchesani‑like syndrome 
and affect disruptions in the extracellular matrix. Hum Mutat 
2012;33:1182‑1187.
Journal of ophthalmic and Vision research 2015; Vol. 10, No. 2 97
Editorial; Sarfarazi
19. Jelodari‑Mamaghani S, Haji‑Seyed‑Javadi R, Suri F, Nilforushan N, 
Yazdani S, Kamyab K, et al. Contribution of the latent 
transforming growth factor‑ß binding protein 2 gene to etiology of 
primary open angle glaucoma and pseudoexfoliation syndrome. 
Mol Vis 2013;19:333‑347.
20. Exome Aggregation Consortium (ExAC). Cambridge, 
MA. Available from: http://www.exac.broadinstitute.org. 
[Last accessed on 2015 May].
21. Kumar D, Eng C. editors. Genomic Medicine: Principles and 
Practice (Oxford Monographs on Medical Genetics). 2nd ed. 
New York: Oxford University Press; 2014.
22. Stone EM, Fingert JH, Alward WL, Nguyen TD, Polansky JR, 
Sunden SL, et al. Identification of a gene that causes primary 
open angle glaucoma. Science 1997;275:668‑670.
23. Stoilov I, Akarsu AN, Sarfarazi M. Identification of three different 
truncating mutations in cytochrome P4501B1 (CYP1B1) as the 
principal cause of primary congenital glaucoma (Buphthalmos) 
in families linked to the GLC3A locus on chromosome 2p21. Hum 
Mol Genet 1997;6:641‑647.
24. Vincent AL, Billingsley G, Buys Y, Levin AV, Priston M, 
Trope G, et al. Digenic inheritance of early‑onset glaucoma: 
CYP1B1, a potential modifier gene. Am J Hum Genet 2002;70:448‑460.
25. Vincent A, Billingsley G, Priston M, Glaser T, Oliver E, 
Walter M, et al. Further support of the role of CYP1B1 in patients 
with Peters anomaly. Mol Vis 2006;12:506‑510.
26. Melki R, Colomb E, Lefort N, Brézin AP, Garchon HJ. CYP1B1 
mutations in French patients with early‑onset primary open‑angle 
glaucoma. J Med Genet 2004;41:647‑651.
27. Pasutto F, Chavarria‑Soley G, Mardin CY, Michels‑Rautenstrauss K, 
Ingelman‑Sundberg M, Fernández‑Martínez L, et al. Heterozygous 
loss‑of‑function variants in CYP1B1 predispose to primary 
open‑angle glaucoma. Invest Ophthalmol Vis Sci 2010;51:249‑254
This is an open access article distributed under the terms of the Creative 
Commons Attribution‑NonCommercial‑ShareAlike 3.0 License, which allows 
others to remix, tweak, and build upon the work non‑commercially, as long as the 
author is credited and the new creations are licensed under the identical terms.






How to cite this article: Sarfarazi M. Common molecular challenges in 
glaucoma. J Ophthalmic Vis Res 2015;10:95-7.
